18 results on '"Laurence Legros"'
Search Results
2. Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study
3. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs)
4. A Retrospective Validation of International Consortium for MDS/MPN Response Criteria in CMML Treated with Hypomethylating Agents
5. Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone
6. Results of a Phase II Study of Guadecitabine in Higher Risk MDS Patients Refractory to or Relapsing after Azacitidine Treatment
7. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
8. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)
9. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients
10. 87 A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM
11. 162 A phase II study of decitabine in advanced chronic myelomonocytic leukemia (CMML)
12. 111 Uniparental disomy (UPD) of P15/INK4 gene is correlated with better hematologic response to azacitidine
13. 59 Myelodysplastic syndromes with isolated neutropenia or thrombocytopenia: Are they refractory cytopenias with unilineage dysplasia? A GFM registry study
14. 174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)?
15. 106 Treatment of advanced CMML by azacitidine (AZA) in a compassionate program. The GFM experience in 38 patients (pts)
16. P107 Treatment of MDS with moderate anemia, not requiring RBC transfusions, by erythropoiesis stimulating agents (ESAs)
17. P111 Long-term outcome of MDS with del 5q before the lenalidomide era. The GFM experience
18. P149 Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): current results of the French ATU program
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.